



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

NHLBI EXTENDS GENEGO LICENSE AGAIN

St. Joseph, MI. September 4th, 2007 –GeneGo, Inc., the leading systems biology tools company, announced today that National Heart Lung and Blood Institute have extended their license again. Hundreds of researchers will have access to MetaCore at the NHLBI for analysis of different types of “omics” data such as gene expression, proteomics, metabolomics and SNPs and MPSS. MetaCore is known for its comprehensive functional ontologies including cellular and molecular processes, canonical metabolic and signaling pathways, diseases and disease networks and biomarkers.

The NHLBI Genomic Core supports NHLBI investigators conducting research with the ultimate goal of understanding the pathophysiology of human diseases employing high throughput technologies. As a central part of its role, the core provides computational and research tools to investigators and helps them expand their ability to conduct genomic research through new techniques mapping gene expression data to metabolic and signaling pathways. Currently investigators sift through large gene lists trying to decipher which pathways are affected. GeneGo’s Metacore data mining software would provide statistical, visual and machine learning techniques to rationalize the extensive changes in gene expression due to experimental conditions or disease processes and DNA sequence variations. It is hoped that the application of this Metacore analysis program would help us decipher the key molecular mechanisms of disease progression, and offer new diagnostic and therapeutic strategies for the future advancement of molecular-based medicine.

“We are pleased to have a strong, long lasting relationship with NIH as they are the best known research organization in biomedicine,” said Julie Bryant, GeneGo’s VP of Business Development. “Over the years, their valuable feedback has helped GeneGo to develop new features and products, and we look forward to expanding relationships with their labs”.

About GeneGo, Inc.

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 5.0™, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The

second product, MetaDrug2.0TM is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBaseTM represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com

MetaCoreTM, MetaBaseTM, MetaDrugTM, MetaLinkTM, MetaDiscoveryTM, MetaToxTM and MetaMinerTM, 1-2-3 WorkflowTM are trademarks of GeneGo, Inc.